Iq-ai Share Discussion Threads

[festario] 04/1/2024 12:10

The bid is currently 4.78p for up to 350k shares.

[clocktower] 04/1/2024 12:05

Good Video and nice to see it still heading to my 7p target slowly.

[festario] 04/1/2024 12:03

I'd never heard of that COO guy, but certainly doesn't come across as some brash, pushy salesman.He's somewhat introverted, but I believe that if the product speaks for itself, the uptake will come.The Bayer guy, he is a practising radiologist too. I hope he has bought a wad of IQAI shares.

[howdlep] 03/1/2024 09:20

This from the October 2023 letter to shareholders. I wonder who the other Q4 installation was with?

Perhaps we will get an RNS, or January newsletter before the webinar?

IB Nimble

Our development team has made tremendous enhancements to our handheld / mobile application, IB Nimble. Specifically, the code base is being re-engineered to enable widespread distribution and efficient support. More work remains, but interest is steadily growing from other brain (mets) cancer centers. As promised, we also deployed IB Nimble for use in a new disease group, metastatic bone cancer, at the Medical College of Wisconsin (MCW). We anticipate at least one more installation in Q4 2023.

Also, we just accepted an invitation to participate in a new initiative launched by the American Brain Tumor Association (ABTS) called the Metastatic Brain Tumor Collaborative. Among other benefits, this is an ideal opportunity to present IB Nimble and IB Clinic to broad audiences throughout 2024.

[spurs90] 02/1/2024 19:44

NIMBLE app expected to be a game-changer for people with brain metastases

The Brain Metastasis Program and the NIMBLE app show promise as game-changers for physicians who need treatment options for their brain metastasis patients.

With NIMBLE, doctors can provide faster access to the experts and resources needed to treat brain metastases. Creating the app was central to launching the Brain Metastases Program and addressing the individual complexity of care for these patients. The NIMBLE app functions as a virtual tumor board that is always available for real-time, doctor-to-doctor discussions. With NIMBLE, the Froedtert & MCW team can offer data-driven treatment recommendations delivered within hours as opposed to days with references to data and publications that support those recommendations. NIMBLE is expected to make treatment options more accessible and to accelerate the treatment path for patients who need it."

While the team hasn't formally published research on the Brain Metastases Program or NIMBLE app, it submitted a paper late in 2019 to an MCW quality symposium. A preliminary study showed that with the expedited, data-driven approach offered by NIMBLE, the typical seven to eight day hospital stay for brain metastasis patients was reduced to about three days. Usually, such patients require involvement from many specialists, and it takes time for all of them to see patients in the hospital. NIMBLE guidance can help resolve this pause — and lower costs.

The app is the only one of its kind in the U.S. and will be available later in 2020 at no cost to physicians through app stores for iOS and Android platforms. NIMBLE offers unique benefits for brain metastasis patients and their doctors:

Decreases the wait: Patients and their doctors don't have to wait for the weekly in-person tumor board for a consultation
Offers immediate recommendations — in hours, not days
Expands resources for cancer providers caring for a brain metastasis patient
Provides a more streamlined path to treatment
Gives a second opinion without having to travel
Reduces hospital stay: For brain metastasis patients who have been admitted to the hospital, length of stay can be reduced by as much as seven days — no waiting for experts to gather to recommend treatment.




Happy New Year! Join us for our next Webinar introducing the advantages of IB Nimble! Read about the app here: [...]
Register Here:

[festario] 02/1/2024 12:36

Looks like Zac's followers have stopped believing in him. He only guesses after all, and he is wrong more than he's right.

[howdlep] 02/1/2024 07:41

Happy New Year to one and all. I fully expect 2024 to be a defining one for IQAI.

Here are the latest bullish comments from Zak Mir:-

Zak notes the V shape bull flag above a rising 50 day moving average, so hopefully that is a strong leading indicator of a move up to the top of the rising trend channel from Feb, pointing at 6.5p. This as soon as the end of this month.

[jpuff] 29/12/2023 15:21

Ditto, good luck all holders here for a good 2024.

[leadersoffice] 29/12/2023 15:16

Hope iQAI can bring us much fortune in 2024. Fingers crossed everyone

[festario] 29/12/2023 09:56

Wouldn't that be something Clocky

[clocktower] 29/12/2023 09:50

Share of the Year for 2024 maybe F.

[spurs90] 29/12/2023 09:47

IQ-AI subsidiary Imaging Biometrics (IB) was awarded a US patent for its artificial intelligence (AI) software technology that eliminates the need for gadolinium-based contrast agents (GBCAs) in medical imaging exams. The fully automated AI technology, called IB Zero G, accepts non-contrast medical images as inputs and produces a synthetic image series that mimics contrast-enhanced images of comparable diagnostic quality. Currently in the investigational stage, IB Zero G is compatible with all MRI system platforms.
Injected intravenously, GBCAs improve diagnostic interpretation of MR imaging by highlighting abnormal areas of internal tissues and structures. Gadolinium, a heavy metal, has special paramagnetic properties which make it useful as a contrast agent. However, gadolinium can stay in a body for years, introducing potential safety and liability concerns for patients and healthcare institutions. While there are no known long-term adverse side effects from retained gadolinium in most patients, certain patients are at higher risk of adverse side effects after receiving GBCAs. IB Zero G offers an extremely attractive alternative for these patients and healthcare providers.
By eliminating the need to acquire a contrast-enhanced series, IB Zero G means less time in the scanner for patients. And for healthcare systems, IB Zero G provides increased scanner availability and a reduction in gadolinium expense.
“This patent underscores the major impact AI applications can have in healthcare,” said Michael Schmainda, CEO of IB. “IB Zero G has the potential to significantly disrupt routine clinical workflows on a global basis and help millions of patients receive higher quality and safer MR exams,” Schmainda added.

[howdlep] 29/12/2023 09:46

Excellent press coverage, dated today:-

[spurs90] 28/12/2023 20:02

Great work by Mona Al-Gizawiy, PhD from the #SchmaindaLab!

Potent in vivo efficacy of oral gallium maltolate in treatment-resistant glioblastoma hxxps://frontiersin.org/articles/10.3389/fonc.2023.1278157

#IBSoftware non-invasively demonstrated the anti-tumor effects of oral GaM.

@AlMusella

@theABTA

[festario] 28/12/2023 15:20

4.2p to sell up to 250k now. Good to see signs of accumulation, even if it is off market.

[festario] 27/12/2023 12:27

Both brokers will take 500k shares above the bid price, which is always encouraging.

[festario] 21/12/2023 08:58

Max to sell with both my brokers, = 0

[clocktower] 20/12/2023 15:32

Every dip is getting a little higher each time it seems F. Hopefully will hold onto it until the New Year.

[festario] 20/12/2023 13:49

You're right Clocky.I never, ever learn.The only way to make money on this or any stock is to sell into the spikes. Unfortunately, the next sell will have a 3 in front of it, which means we are no better off than before this latest RNS.

[festario] 20/12/2023 08:16

You can't sell a single share with either of my brokers this morning. Such a shame.

[howdlep] 20/12/2023 07:51

Here's a ChatGBT summary of the RNS (Regulatory News Service) announcement regarding IQ-AI Ltd's subsidiary, Imaging Biometrics (IB), and the implications of their recent FDA Fast-Track designation for oral gallium maltolate (GaM) in treating glioblastoma (GBM):

Summary of RNS:

Company Involved: Imaging Biometrics, LLC, a subsidiary of IQ-AI Ltd.
Announcement: The U.S. FDA has granted Fast-Track designation to IB's oral gallium maltolate (GaM) for treating adult patients with relapsed or refractory glioblastoma (GBM), IDH-wildtype.

Significance of FDA Decision: Reflects the urgency and unmet medical need in treating GBM. Oral GaM has also received Orphan Drug designation, highlighting its potential in addressing this critical area.

Benefits of Fast-Track Designation: Enables an accelerated review process with the FDA. This involves increased communication and collaboration, aimed at speeding up the development and approval process.

Company's Response: Trevor Brown, CEO of IQ-AI, expressed satisfaction with this milestone and emphasized commitment to working closely with the FDA to fast-track the clinical development of oral GaM.

Implications and Bullet Points:

Accelerated Development and Approval: Fast-Track designation means quicker development and potential approval of oral GaM, which could lead to faster patient access.

Addressing Unmet Medical Needs: GBM is a severe and currently underserved medical condition. This designation underlines the treatment's importance in filling a significant therapeutic gap.

Increased FDA Interaction: The designation allows for more frequent communication with the FDA, possibly leading to more efficient development processes.

Market Positioning: This milestone enhances the market positioning of IQ-AI and its subsidiary, potentially leading to commercial advantages.

Investor Confidence: Such regulatory milestones can positively impact investor confidence, reflecting the potential success and viability of the treatment.

Enhanced Corporate Reputation: Receiving Fast-Track status boosts the company's reputation in the biotech and pharmaceutical industry, potentially opening doors for future collaborations and investments.

[hatfullofsky] 19/12/2023 19:03

This will get some coverage tomorrow and still below £10m

[hatfullofsky] 19/12/2023 18:58

Now's not the time to get rid of EVG, wait for the news / excuses and then decide